Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AbSci ( (ABSI) ) has provided an announcement.
On July 7, 2025, Absci Corporation appointed Mary Szela to its Board of Directors, expanding the board to seven members. Ms. Szela, who is also the CEO, President, and Director of Trisalus Life Sciences, will serve as a Class III director until the 2027 annual meeting. She was granted an option to purchase 178,400 shares of the company’s stock, which will vest monthly over three years, and will receive an annual $40,000 cash retainer.
The most recent analyst rating on (ABSI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on AbSci stock, see the ABSI Stock Forecast page.
Spark’s Take on ABSI Stock
According to Spark, TipRanks’ AI Analyst, ABSI is a Neutral.
AbSci’s overall score reflects significant financial challenges, with substantial risks in profitability and cash flow. However, technical indicators and corporate developments provide some optimism. Strategic progress in clinical trials and AI initiatives, along with improved corporate governance, offer potential for future growth.
To see Spark’s full report on ABSI stock, click here.
More about AbSci
Average Trading Volume: 3,188,839
Technical Sentiment Signal: Sell
Current Market Cap: $329.1M
For detailed information about ABSI stock, go to TipRanks’ Stock Analysis page.